Status:
ACTIVE_NOT_RECRUITING
Investigation to Determine Safety of Taperloc Stems With BioGuard Coating When Used in Cementless Total Hip Arthroplasty
Lead Sponsor:
Zimmer Biomet
Conditions:
Osteoarthritis of Hip
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
Prospective clinical investigation to determine the safety of Taperloc stems with BioGuard coating and Exceed ABT Taperfit acetabular cups with BioGuard coating when used in cementless total hip arthr...
Detailed Description
Bioguard Safety Study: Prospective clinical investigation to determine the safety of Taperloc stems with BioGuard coating and Exceed ABT Taperfit acetabular cups with BioGuard coating when used in cem...
Eligibility Criteria
Inclusion
- Eligible for cementless primary total hip arthroplasty according to the Surgical Technique brochure (Appendix 10): "The Taperloc Porous Primary Hip and Exceed ABT Taperfit Prostheses are marketed for non-cemented use in skeletally mature patients undergoing primary hip replacement surgery of non inflammatory degenerative joint disease."
- Under 80 and over 40 years of age
- A pre-operative level of pain and function the same as for conventional joint replacement.
- A likelihood of obtaining relief of pain and improved function
- Full skeletal maturity
- Ability to follow instructions
- Good general health for age
- Willing to return for follow-up evaluations
Exclusion
- Patients aged over 80 and under 40 years
- Known allergy to any antibiotics
- Active infection
- Revision arthroplasty
- Marked bone loss which could preclude or compromise adequate fixation of the device
- Uncooperative subjects
- Parkinson's Disease
- Vascular insufficiency of the affected limb, which could compromise bony ingrowth/implant fixation, i.e., diabetes.
- Severe instability or deformity of the ligaments and/or surrounding soft tissue which may preclude stability of the device
- Pregnancy
- BMI \> 40
- Use of immunosuppressive drugs
- Women of child bearing potential
Key Trial Info
Start Date :
October 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT02263209
Start Date
October 1 2013
End Date
May 1 2025
Last Update
August 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RJAH
Oswestry, United Kingdom